orforglipron semaglutide HUGE news in the GLP-1 space! has outperformed oral in the ACHIEVE-3 clinical trial in patients with type 2 diabetes. Comment your thoughts below! ⬇️ Orforglipron and semaglutide, Comparison

Metformin causes a futile intestinal-hepatic cycle which increases energy expenditure and slows down development of a type 2 diabetes-like state

and further four biomarkers are placed into categories such as diagnostic, predictive, prognostic and exposure

doi: 10.1152/ajplung.1998.274.6.L970 405 DantzerR

Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and weight management, raising questions about its effects on eye health

Furthermore, our data also suggest that genotype results based on the 5UTR pattern of the Versant 2.0, in case of core pattern 23 only, can be considered conclusive

We would not consider this solution viable for reliable research